DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ ...

The device, called Biolinq Shine, is indicated for people with Type 2 diabetes who don’t depend on insulin. Biolinq says its ...

Dexcom faces mounting scrutiny over G7 safety concerns, FDA violations, financial practices, and growing competition from ...

DexCom (DXCM) stock declines after a short report, yet analysts from TD Cowen and Baird stay bullish on the company's ...

ViCentra's Kaleido is "the smallest, thinnest, lightest, most precise insulin patch pump in its class," CEO Tom Arnold said ...

At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring ...

The report claims that inaccurate readings from the G7 device have resulted in hospitalizations and deaths among diabetic patients. According to Hunterbrook, an FDA inspection revealed DexCom made an ...

Next presentation this afternoon is from DexCom, a leader in developing and commercializing continuous glucose monitoring systems for people with diabetes and I'm sure in the future beyond diabetes.

Flavia Pease will take over as Insulet’s CFO on Sept. 30. Elsewhere, outgoing Dexcom CEO Kevin Sayer is taking a medical ...

Here are four of the latest recalls and corrections reported to the FDA.

The San Diego-based company claims a number of firsts for its coin-sized Biolinq Shine device, including that it is so far ...